Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
Free Cash Flow
Mereo Biopharma Group PLC
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Free Cash Flow
-£38.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Free Cash Flow
-$160.5m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Free Cash Flow
-$156.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Free Cash Flow
-$85.9m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Free Cash Flow
-£2.5m
|
CAGR 3-Years
66%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Free Cash Flow
£10m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-9%
|
See Also
What is Mereo Biopharma Group PLC's Free Cash Flow?
Free Cash Flow
-38.8m
GBP
Based on the financial report for Dec 31, 2022, Mereo Biopharma Group PLC's Free Cash Flow amounts to -38.8m GBP.
What is Mereo Biopharma Group PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
5%
Over the last year, the Free Cash Flow growth was -572%. The average annual Free Cash Flow growth rates for Mereo Biopharma Group PLC have been 5% over the past three years .